Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review

Yuke Wu, Xiang He
{"title":"Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review","authors":"Yuke Wu, Xiang He","doi":"10.31083/j.ceog5107155","DOIUrl":null,"url":null,"abstract":"Objectives : This review aims to summarize the current literature on recurrent and metastatic (r/m) cervical cancer, especially first-line and second-line immunotherapy. Clinical benefits including efficacy and safety of new therapeutic options are also reviewed. Mechanism : The published relevant articles were searched from multiple databases, including PubMed, Ovid, and Scopus. The key terms included recurrent cervical cancer, advanced cervical cancer, metastatic cervical cancer, and immunotherapy. The data of the latest clinical trials was retrieved from ClinicalTrials.gov (https://clinicaltrials.gov). Findings in Brief : In late 2021, pembrolizumab in combination with chemotherapy with or without bevacizumab was approved as the first-line treatment for recurrent and metastatic cervical cancer. Also tisotumab vedotin was approved as the second-line immunotherapy for r/m cervical cancer. Moreover, a plethora of clinical immunotherapy trials were approved in different countries, and some received as breakthrough therapy designations. Pembrolizumab, cemiplimab, atezolizumab, cadonilimab, zimberelimab, balstilimab and zalifrelimab, nivolumab, and tisotumab vedotin were reviewed with overall survival, progression-free survival, rate of objective response and adverse effects in order to review the efficacy and safety of different therapeutic option. Conclusions : The majority of trials indicated that immunotherapy can significantly improve the overall survival (OS) and progression-free survival (PFS) of r/m cervical cancer patients without negatively affecting health-related quality-of-life (HRQoL), and demonstrated that immunotherapy is an effective and safe treatment for r/m cervical cancer.","PeriodicalId":505527,"journal":{"name":"Clinical and Experimental Obstetrics & Gynecology","volume":"123 13","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Obstetrics & Gynecology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31083/j.ceog5107155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives : This review aims to summarize the current literature on recurrent and metastatic (r/m) cervical cancer, especially first-line and second-line immunotherapy. Clinical benefits including efficacy and safety of new therapeutic options are also reviewed. Mechanism : The published relevant articles were searched from multiple databases, including PubMed, Ovid, and Scopus. The key terms included recurrent cervical cancer, advanced cervical cancer, metastatic cervical cancer, and immunotherapy. The data of the latest clinical trials was retrieved from ClinicalTrials.gov (https://clinicaltrials.gov). Findings in Brief : In late 2021, pembrolizumab in combination with chemotherapy with or without bevacizumab was approved as the first-line treatment for recurrent and metastatic cervical cancer. Also tisotumab vedotin was approved as the second-line immunotherapy for r/m cervical cancer. Moreover, a plethora of clinical immunotherapy trials were approved in different countries, and some received as breakthrough therapy designations. Pembrolizumab, cemiplimab, atezolizumab, cadonilimab, zimberelimab, balstilimab and zalifrelimab, nivolumab, and tisotumab vedotin were reviewed with overall survival, progression-free survival, rate of objective response and adverse effects in order to review the efficacy and safety of different therapeutic option. Conclusions : The majority of trials indicated that immunotherapy can significantly improve the overall survival (OS) and progression-free survival (PFS) of r/m cervical cancer patients without negatively affecting health-related quality-of-life (HRQoL), and demonstrated that immunotherapy is an effective and safe treatment for r/m cervical cancer.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
复发性和转移性宫颈癌的免疫疗法:综述
目的:本综述旨在总结目前有关复发性和转移性(r/m)宫颈癌的文献,尤其是一线和二线免疫疗法。此外,还综述了新治疗方案的临床优势,包括疗效和安全性。研究机制:从多个数据库(包括 PubMed、Ovid 和 Scopus)中检索已发表的相关文章。关键词包括复发性宫颈癌、晚期宫颈癌、转移性宫颈癌和免疫疗法。最新临床试验数据来自 ClinicalTrials.gov (https://clinicaltrials.gov)。研究结果简介:2021 年底,pembrolizumab 与化疗联合或不联合贝伐单抗被批准作为复发性和转移性宫颈癌的一线治疗方法。同时,tisotumab vedotin 也被批准作为复发性和转移性宫颈癌的二线免疫疗法。此外,各国还批准了大量临床免疫疗法试验,其中一些还获得了突破性疗法称号。我们对 Pembrolizumab、cemiplimab、atezolizumab、cadonilimab、zimberelimab、balstilimab 和 zalifrelimab、nivolumab 和 tisotumab vedotin 的总生存期、无进展生存期、客观反应率和不良反应进行了回顾,以评估不同治疗方案的有效性和安全性。结论 :大多数试验表明,免疫疗法可显著改善r/m宫颈癌患者的总生存期(OS)和无进展生存期(PFS),且不会对健康相关生活质量(HRQoL)产生负面影响,并证明免疫疗法是治疗r/m宫颈癌有效且安全的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Role of Neoadjuvant Chemotherapy in High-Grade Neuroendocrine Carcinoma of the Uterine Cervix Risk Factors for Endometrial Cancer in the World: A Narrative Review of the Recent Literature Effects of SARS-CoV-2 Infection on Menstruation in Vaccinated Women: A Monocentric Retrospective Study Comparative Study of the Effects of Sublingual Trinitroglycerin and Sublingual Misoprostol on Cervical Preparation before Hysteroscopy: A Randomized Controlled Trial Effect of Low-Frequency Electrical Stimulation Combined with Abdominal Acupoint Massage on Postoperative Gastrointestinal Function Recovery after Cesarean Section: A Prospective Randomized Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1